CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
Sign Up to like & getrecommendations! Published in 2019 at "Brain and Behavior"
DOI: 10.1002/brb3.1215
Abstract: CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the… read more here.
Keywords: migraine; meta analysis; chronic migraine; preventive treatment ... See more keywords
Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Rheumatology"
DOI: 10.1007/s10067-020-05072-w
Abstract: To elicit and compare preferences of patients and first-degree relatives and rheumatologists for preventive treatments for rheumatoid arthritis, understand the influence of shared decision-making, and predict the probability of uptake of the preventive treatments currently… read more here.
Keywords: shared decision; treatment; patients first; decision making ... See more keywords
Galcanezumab: First Global Approval
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-1002-7
Abstract: Galcanezumab-gnlm (Emgality™; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand. A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis. In September 2018,… read more here.
Keywords: migraine; galcanezumab; galcanezumab first; migraine adults ... See more keywords
Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.
Sign Up to like & getrecommendations! Published in 2019 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2018.12.011
Abstract: BACKGROUND Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system (CNS) that preferentially targets the spinal cord and optic nerves. Increasing disability is accrued with each inflammatory attack. Disability has… read more here.
Keywords: delay diagnosis; diagnosis; disability; diagnosis preventive ... See more keywords
Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome
Sign Up to like & getrecommendations! Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-28314-z
Abstract: Wolfram syndrome (WS) is a rare autosomal recessive disorder caused by mutations in the WFS1 (Wolframin1) gene. The syndrome first manifests as diabetes mellitus, followed by optic nerve atrophy, deafness, and neurodegeneration. The underlying mechanism… read more here.
Keywords: glucose intolerance; treatment; wolfram syndrome; development glucose ... See more keywords
Exploring preferences of at-risk individuals for preventive treatments for rheumatoid arthritis.
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian journal of rheumatology"
DOI: 10.1080/03009742.2022.2116805
Abstract: OBJECTIVE Some immunomodulatory drugs have been shown to delay the onset of, or lower the risk of developing, rheumatoid arthritis (RA), if given to individuals at risk. Several trials are ongoing in this area; however,… read more here.
Keywords: preventive treatments; rheumatoid arthritis; risk; treatment ... See more keywords
Fremanezumab as a preventive treatment for episodic and chronic migraine
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2019.1614742
Abstract: ABSTRACT Introduction: The importance of calcitonin gene-related peptide (CGRP) in migraine pathogenesis is well established. Fremanezumab is a humanized IgG2a monoclonal antibody that binds to CGRP. Areas covered: In this paper, we review the development… read more here.
Keywords: migraine; treatment episodic; episodic chronic; fremanezumab preventive ... See more keywords
New and current preventive treatment options in actinic keratosis
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.14375
Abstract: Actinic keratosis (AK) is a characteristic skin lesion on skin areas of subjects with mainly phototype I and phototype II, or with specific genetic factors and who are exposed to prolonged ultraviolet radiation. AK may… read more here.
Keywords: current preventive; treatment; treatment options; new current ... See more keywords
The social dimensions of community delivery of intermittent preventive treatment of malaria in pregnancy in Madagascar, Mozambique, Nigeria and the Democratic Republic of the Congo
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Global Health"
DOI: 10.1136/bmjgh-2022-010079
Abstract: Introduction Intermittent preventive treatment in pregnancy with sulphadoxine pyrimethamine (IPTp) is a key malaria prevention strategy in sub-Saharan African countries. We conducted an anthropological study as part of a project aiming to evaluate a community-based… read more here.
Keywords: iptp; community; pregnancy; preventive treatment ... See more keywords
Effectiveness of women-led community interventions in improving tuberculosis preventive treatment in children: results from a comparative, before–after study in Ethiopia
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2022-062298
Abstract: Objectives Our objective was to evaluate the impact of a service delivery model led by membership-based associations called Iddirs formed by women on tuberculosis preventive treatment (TPT) initiation and completion rates among children. Design Comparative,… read more here.
Keywords: comparative study; tpt; tpt initiation; treatment ... See more keywords
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
Sign Up to like & getrecommendations! Published in 2023 at "Cephalalgia"
DOI: 10.1177/03331024221128250
Abstract: Background Atogepant is a United States Food and Drug Administration-approved oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine. The study objective was to evaluate the long-term safety and tolerability of… read more here.
Keywords: safety; treatment episodic; trial; week ... See more keywords